Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Jolt accentuation of headache: can this maneuver rule out acute meningitis?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence and significance of Mycoplasma genitalium in women living with HIV in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Control interventions in randomised trials among people with mental health disorders

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

OBJECTIVE: We present the statistical analysis plan of a prespecified Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage (TICH)-2 sub-study aiming to investigate, if tranexamic acid has a different effect in intracerebral haemorrhage patients with the spot sign on admission compared to spot sign negative patients. The TICH-2 trial recruited above 2000 participants with intracerebral haemorrhage arriving in hospital within 8 h after symptom onset. They were included irrespective of radiological signs of on-going haematoma expansion. Participants were randomised to tranexamic acid versus matching placebo. In this subgroup analysis, we will include all participants in TICH-2 with a computed tomography angiography on admission allowing adjudication of the participants' spot sign status.

RESULTS: Primary outcome will be the ability of tranexamic acid to limit absolute haematoma volume on computed tomography at 24 h (± 12 h) after randomisation among spot sign positive and spot sign negative participants, respectively. Within all outcome measures, the effect of tranexamic acid in spot sign positive/negative participants will be compared using tests of interaction. This sub-study will investigate the important clinical hypothesis that spot sign positive patients might benefit more from administration of tranexamic acid compared to spot sign negative patients. Trial registration ISRCTN93732214 ( http://www.isrctn.com ).

Original languageEnglish
JournalBMC Research Notes
Volume11
Issue number1
Pages (from-to)379
ISSN1756-0500
DOIs
Publication statusPublished - 13 Jun 2018

ID: 54612928